Cardiovascular Drugs and Therapy

, Volume 25, Issue 1, pp 105–106 | Cite as

Phosphatidylcholine-Rich Nanoliposomes: Potential Tools for Serum C-Reactive Protein Reduction?

  • Amirhossein Sahebkar
Letter to the Editor


Kupffer Cell Foam Cell Acid Hydrolase Cardiovascular Risk Assessment Constituent Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMedCrossRefGoogle Scholar
  3. 3.
    Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Montecoccu F, Mach F. Therapeutic approaches for reducing c-reactive protein (CRP) levels and the associated cardiovascular risk. Curr Chem Biol. 2009;3:380–4.CrossRefGoogle Scholar
  5. 5.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.PubMedGoogle Scholar
  6. 6.
    Peng YN, Ho YL, Wu CY, et al. Investigation of C-reactive protein binding to phosphatidyl choline by CZE and ESI-mass analysis. Electrophoresis. 2009;30:1564–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002;366:195–201.PubMedGoogle Scholar
  8. 8.
    Pentikäinen MO, Oörni K, Ala-Korpela M, et al. Modified LDL—trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 2000;247:359–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99:13043–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Mozafari MR. Nanoliposomes: Preparation and Analysis. Methods Mol Biol. 2010;605:29–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Maximov VD, Reukov VV, Barry JN, et al. Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology. 2010;21:265103.PubMedCrossRefGoogle Scholar
  12. 12.
    Mackiewicz MR, Hodges HL, Reed SM. C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. J Phys Chem B. 2010;114:5556–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Liuzzo G, Santamaria M, Biasucci LM, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 2007;49:185–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Cardiovascular Research Center, Avicenna Research InstituteMashhad University of Medical Sciences (MUMS)MashhadIran
  2. 2.Biotechnology Research Center and School of PharmacyMashhad University of Medical Sciences (MUMS)MashhadIran

Personalised recommendations